Paper - WANFANG MED ONLINE

You Position: Home > Paper

Value of fecal calprotectin in diagnosis of ulcerative colitis

( views:405, downloads:65 )

Author:: No author available

Journal Title:: WORLD CHINESE JOURNAL OF DIGESTOLOGY

Issue:: 30

DOI:: 10.3969/j.issn.1009-3079.2007.30.011

Key Word:: 钙卫蛋白;溃疡性结肠炎;ELISA方法

Abstract：目的:研究粪便钙卫蛋白检测作为一种无创性方法用于诊断溃疡性结肠炎(UC)活动性的价值.方法:UC患者82例,60例经结肠镜检查正常的患者作为对照,留取结肠镜检查1wk内的粪便样本10g,采用ELISA方法进行粪便钙卫蛋白检测.对23例活动期3级患者实施随访,监测粪便钙卫蛋白水平,用于指导临床治疗用药并观察疗效.结果:UC缓解期组粪便钙卫蛋白水平和正常对照组之间差异无统计学意义,活动期粪便钙卫蛋白水平与缓解期和正常对照组比均有统计学意义(603.2μg/g vs 8.2μg/g,6.6μg/g,P＜0.01),活动期1级(103.5μg/g)、2级(582.9μg/g)和3级(1340.6μg/g)两两比较差异均有统计学意义(P＜0.01).粪便钙卫蛋白水平与UC内镜分级显著相关(r=0.89,P＜0.01).UC活动期3级患者23例经治疗后至缓解期,粪便钙卫蛋白水平显著下降,其治疗前后相比差异有统计学意义(1383.5μg/g vs 8.0μg/g,P＜0.01).结论:粪便钙卫蛋白能较准确地诊断UC活动期和缓解期,用于指导临床治疗较好.

Reference

[1]江学良,权启镇,王志奎.溃疡性结肠炎的诊断、分型及疗效标准[J].2000,(3).
[2]陈振华,邵先玉.溃疡性结肠炎的X线和肠镜检查[J].2000,(3).
[3]中华医学会消化病学分会.对炎症性肠病诊断治疗规范的建议[J].2001,(4).
[4]M, Seo,M, Okada,T, Yao,etc.Evaluation of disease activity in patients with moderately active ulcerative colitis: comparisons between a new activity index and Truelove and Witts' classification.[J].1995,90.
[5]Valanzano R,Cellai AP,Prisco D,etc.Hemostatic abnormalities in inflammatory bowel disease.[J].1996,82(2).
[6]Sandborn WJ.Correlation of C-Reactive Protein with Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease.[J].2005,11(8).
[7]J, Sander,M K, Fagerhol,J S, Bakken,etc.Plasma levels of the leucocyte L1 protein in febrile conditions: relation to aetiology, number of leucocytes in blood, blood sedimentation reaction and C-reactive protein.[J].1984,44.
[8]S C, TRUELOVE,L J, WITTS.Cortisone in ulcerative colitis; final report on a therapeutic trial.[J].1955,2(4947).
[9]P, J?remo,H, Sandberg-Gertzen.Platelet density and size in inflammatory bowel disease.[J].1996,75.
[10]J F, Martínez Salmerón,M, Rodrigo,F, Nogueras,etc.[Comparison of the indexes of serologic activity with endoscopy in intestinal inflammatory disease].[J].1900,19(7).
[11]C K, Ameho,A A, Adjei,E K, Harrison,etc.Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis.[J].1997,41(4).
[12]MLampinen,ARo&#776,nnblom,etc.Eosinophil granulocytes are activated during the remission phase of ulcerative colitis[J].2005,54(12).
[13]J G, Brun,G, H?land,H J, Haga,etc.Effects of calprotectin in avridine-induced arthritis.[J].1995,103.
[14]B, Johne,M K, Fagerhol,T, Lyberg,etc.Functional and clinical aspects of the myelomonocyte protein calprotectin.[J].1997,50.
[15]I, Gouni-Berthold,B, Baumeister,H K, Berthold,etc.Immunoglobulins and IgG subclasses in patients with inflammatory bowel disease.[J].1900,46.
[16]Andrew, Poullis,R, Foster,Michael A, Mendall,etc.Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity.[J].2003,15(5).
[17]T R, Meling,L, Aabakken,A, R?seth,etc.Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs.[J].1996,31.
[18]Jung Su, Ha,June Sang, Lee,Hoi Jin, Kim,etc.[Comparative usefulness of erythrocyte sedimentation rate and C-reactive protein in assessing the severity of ulcerative colitis].[J].2006,48(5).
[19]Moodie SJ,Risley P,Theodossi A,etc.A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders.[J].2002,14(4).
[20]C, Kerkhoff,M, Klempt,C, Sorg.Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9).[J].1998,1448.
[21]Claudio Fiocchi.Inflammatory bowel disease: Etiology and pathogenesis[J].1998,115(1).
[22]Philipsen EK,Bondesen S,Andersen J,etc.Serum immunoglobulin G subclasses in patients with ulcerative colitis and Crohn's disease of different disease activities.[J].1995,30(1).
[23]Selicato F,Penna A,Mastronardi ML,etc.New insights into the biological and clinical significance of fecal calprotectin in inflammatory bowel disease.[J].2006,28(4).
[24]J G, Brun,H J, Haga,E, B?e,etc.Calprotectin in patients with rheumatoid arthritis: relation to clinical and laboratory variables of disease activity.[J].1992,19.
[25]J. Powell-Tuck,D. W. Day,N. A. Buckell,etc.Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis[J].1982,27(6).